Abstract
Obesity is a well-known risk factor for the development of insulin resistance, type 2 diabetes, dyslipidemia, hypertension, and cardiovascular disease. Rather than the total amount of fat, central distribution of adipose tissue is very important in the pathophysiology of this constellation of abnormalities termed metabolic syndrome. Adipose tissue, regarded only as an energy storage organ until the last decade, is now known as the biggest endocrine organ of the human body. This tissue secretes a number of substances - adipocytokines - with multiple functions in metabolic profile and immunological process. Therefore, excessive fat mass may trigger metabolic and hemostatic disturbances as well as CVD. Adipocytokines may act locally or distally as inflammatory, immune or hormonal signalers. In this review we discuss visceral obesity, the potential mechanisms by which it would be related to insulin resistance, methods for its assessment and focus on the main adipocytokines expressed and secreted by the adipose tissue. Particularly, we review the role of adiponectin, leptin, resistin, angiotensinogen, TNF-α , and PAI-1, describing their impact on insulin resistance and cardiovascular risk, based on more recent findings in this area.
Keywords: Adipocytokines, Visceral obesity, Insulin resistance, Metabolic syndrome, Adipose tissue
Current Diabetes Reviews
Title: The New Adipose Tissue and Adipocytokines
Volume: 2 Issue: 1
Author(s): Caroline Bulcao, Sandra R. G. Ferreira, Fernando M.A. Giuffrida and Fernando F. Ribeiro-Filho
Affiliation:
Keywords: Adipocytokines, Visceral obesity, Insulin resistance, Metabolic syndrome, Adipose tissue
Abstract: Obesity is a well-known risk factor for the development of insulin resistance, type 2 diabetes, dyslipidemia, hypertension, and cardiovascular disease. Rather than the total amount of fat, central distribution of adipose tissue is very important in the pathophysiology of this constellation of abnormalities termed metabolic syndrome. Adipose tissue, regarded only as an energy storage organ until the last decade, is now known as the biggest endocrine organ of the human body. This tissue secretes a number of substances - adipocytokines - with multiple functions in metabolic profile and immunological process. Therefore, excessive fat mass may trigger metabolic and hemostatic disturbances as well as CVD. Adipocytokines may act locally or distally as inflammatory, immune or hormonal signalers. In this review we discuss visceral obesity, the potential mechanisms by which it would be related to insulin resistance, methods for its assessment and focus on the main adipocytokines expressed and secreted by the adipose tissue. Particularly, we review the role of adiponectin, leptin, resistin, angiotensinogen, TNF-α , and PAI-1, describing their impact on insulin resistance and cardiovascular risk, based on more recent findings in this area.
Export Options
About this article
Cite this article as:
Bulcao Caroline, Ferreira R. G. Sandra, Giuffrida M.A. Fernando and Ribeiro-Filho F. Fernando, The New Adipose Tissue and Adipocytokines, Current Diabetes Reviews 2006; 2 (1) . https://dx.doi.org/10.2174/157339906775473617
DOI https://dx.doi.org/10.2174/157339906775473617 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Bilayer Tablet Based Chronotherapeutics in the Management of Nocturnal Asthma: An Overview
Recent Patents on Drug Delivery & Formulation Cigarette Smoking is Associated with Decreased Bone Gla-protein (BGP) Levels in Hemodialysis Patients
Current Vascular Pharmacology Impaired Renal Autoregulation in Susceptible Models of Renal Disease
Current Vascular Pharmacology Hydrogen Sulfide-Based Therapies: Focus on H2S Releasing NSAIDs
Inflammation & Allergy - Drug Targets (Discontinued) Current Reviews on Renal Vein Thrombosis in Neonates
Current Pediatric Reviews Editorial [Hot Topic: Latest Developments in Pharmaceutical Design of Arachidonic Acid Metabolites: Prostaglandins, Thromboxanes, Hepoxilins and Isoprostanes (Executive Editors: J.-M. Dogne and K.-H. Ruan )]
Current Pharmaceutical Design Effect on Morphology, Osmotic Fragility and Electro Kinetic Potential of Erythrocytes in Hypertension
Current Hypertension Reviews Recurrent Gastrointestinal Bleeding in a Patient with Eisenmenger Syndrome Using Bosentan
Current Drug Safety Correlation Between Circulating Adhesion Molecules and Resistin Levels in Hypertensive Type-2 Diabetic Patients
Inflammation & Allergy - Drug Targets (Discontinued) A Systematic Approach to Assess the Burden of Drug Interactions in Adult Kidney Transplant Patients
Current Drug Safety Neuropeptide Conversion to Bioactive Fragments - An Important Pathway in Neuromodulation
Current Protein & Peptide Science Circulating Endothelial Progenitor Cells Biology and Regenerative Medicine in Pulmonary Vascular Diseases
Current Pharmaceutical Biotechnology Mambalgins, the Venom-origin Peptides as a Potentially Novel Group of Analgesics: Mini Review
CNS & Neurological Disorders - Drug Targets Foreword [ Current Vascular Pharmacology is 10 Years Old! ]
Current Vascular Pharmacology The Evaluation and Management of Adult-Onset Henoch-Schonlein Purpura
Current Rheumatology Reviews Concepts of Egr-1 Activation – A Hub for Signal Transduction Cascades
Current Signal Transduction Therapy Biochemical Markers in the Prediction of Contrast-induced Acute Kidney Injury
Current Medicinal Chemistry Cigarette Smoking and Angiogenesis: What is the Role of Endothelial Progenitor Cells?
Current Angiogenesis (Discontinued) Functional Genomics of the Oxidative Stress Pathway
Current Hypertension Reviews New Pharmacological Perspectives and Therapeutic Potential of PPAR-γ Agonists
Current Pharmaceutical Design